6-(3-Isobutoxy-5-isopropoxy-benzoylamino)-nicotinic acid methyl ester | 499991-81-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-(3-Isobutoxy-5-isopropoxy-benzoylamino)-nicotinic acid methyl ester
• 英文别名: Methyl 6-[(3-isobutoxy-5-isopropoxybenzoyl)amino]-3-pyridinecarboxylate；methyl 6-[[3-(2-methylpropoxy)-5-propan-2-yloxybenzoyl]amino]pyridine-3-carboxylate
• CAS: 499991-81-0
• 化学式: C₂₁H₂₆N₂O₅
• 分子量: 386.448
• InChiKey: VJRBUISFXGRYPB-UHFFFAOYSA-N

物化性质

• 沸点：
  480.9±45.0 °C(Predicted)
• 密度：
  1.168±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  86.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  6-(3-Isobutoxy-5-isopropoxy-benzoylamino)-nicotinic acid methyl ester 在 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 以90%的产率得到6-[(3-isobutoxy-5-isopropoxybenzoyl)amino]nicotinic acid
  参考文献：
  名称：

  Discovery, synthesis and biological evaluation of novel glucokinase activators

  摘要：

  The identification, synthesis and SAR of a novel series of glucokinase activators is described. The interplay between lipophilicity, potency and physical properties is discussed, and compound 22 highlighted as having a suitable balance. In vivo pharmacokinetic and acute efficacy studies on this compound are also presented. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.01.087
• 作为产物：
  描述：

  3-Isobutoxy-5-isopropoxy-benzoic acid 在 吡啶 、 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 6-(3-Isobutoxy-5-isopropoxy-benzoylamino)-nicotinic acid methyl ester
  参考文献：
  名称：

  Discovery, synthesis and biological evaluation of novel glucokinase activators

  摘要：

  The identification, synthesis and SAR of a novel series of glucokinase activators is described. The interplay between lipophilicity, potency and physical properties is discussed, and compound 22 highlighted as having a suitable balance. In vivo pharmacokinetic and acute efficacy studies on this compound are also presented. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.01.087

文献信息

• [EN] AMINO NICOTINATE DERIVATIVES AS GLUCOKINASE (GLK) MODULATORS<br/>[FR] DERIVES D'AMINONICOTINATE JOUANT LE ROLE DE MODULATEURS DE GLUCOKINASE (GLK)
  申请人：ASTRAZENECA AB

  公开号：WO2003000267A1

  公开（公告）日：2003-01-03

  The invention related to novel compounds of Formula (I) or a salt, solvate or prodrug thereof, wherein R?1?, R2, R3, n and m are as described in the specification, useful in the treatment of a (A chemical formula should be inserted here - please see paper copy enclosed) Formula (I) disease or condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to methods for preparing compounds of Formula (I) and their use as medicaments in the treatment of diseases mediated by glucokinase.

  本发明涉及一种新型化合物的公式（I）或其盐，溶剂化物或前药，其中R?1？，R2，R3，n和m如规范中所述，对治疗通过葡萄糖激酶（GLK）介导的（这里应插入一种化学式-请参见随附的纸质副本）公式（I）疾病或病况有用，例如2型糖尿病。本发明还涉及制备公式（I）化合物的方法及其作为治疗由葡萄糖激酶介导的疾病的药物的用途。
• Compounds effecting glucokinase
  申请人：Boyd Scott

  公开号：US20050080106A1

  公开（公告）日：2005-04-14

  The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R 1 , R 2 , R 3 , n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).

  本发明涉及使用式(I)化合物或其盐、溶剂化物或前药，其中R1、R2、R3、n和m如规范中所述，用于制备治疗或预防通过葡萄糖激酶（GLK）介导的疾病状态，例如2型糖尿病的药物。本发明还涉及一种新的式(I)化合物群以及制备式(I)化合物的方法。
• Amino nicotinate derivatives as glucokinase (GLK) modulators
  申请人：——

  公开号：US20040214868A1

  公开（公告）日：2004-10-28

  The invention related to novel compounds of Formula (I) or a salt, solvate or prodrug thereof, wherein R 1 , R 2 , R 3 , n and m are as described in the specification, useful in the treatment of a 1 disease or condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to methods for preparing compounds of Formula (I) and their use as medicaments in the treatment of diseases mediated by glucokinase.

  该发明涉及式（I）的新化合物或其盐，溶剂化合物或前药，其中R1，R2，R3，n和m如规范所述，在通过葡萄糖激酶（GLK）介导的疾病或症状的治疗中有用，例如2型糖尿病。该发明还涉及制备式（I）化合物的方法，以及它们作为药物治疗由葡萄糖激酶介导的疾病的用途。
• COMPOUNDS EFFECTING GLUCOKINASE
  申请人：BOYD Scott

  公开号：US20090227592A1

  公开（公告）日：2009-09-10

  The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R 1 , R 2 , R 3 , n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).

  本发明涉及使用式（I）化合物或其盐、溶剂化物或前药，在制备用于治疗或预防通过葡萄糖激酶（GLK）介导的疾病状态，如2型糖尿病的药物。本发明还涉及一种新的式（I）化合物群以及制备式（I）化合物的方法。其中，R1、R2、R3、n和m如规范中所述。
• Compounds Effecting Glucokinase
  申请人：Boyd Scott

  公开号：US20080207636A1

  公开（公告）日：2008-08-28

  The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R 1 , R 2 , R 3 , n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).

  本发明涉及使用化合物式(I)或其盐、溶剂化物或前药，其中R1、R2、R3、n和m如规范所述，在制备治疗或预防通过葡萄糖激酶（GLK）介导的疾病状态，如2型糖尿病的药物。本发明还涉及一类新的化合物式(I)和制备化合物式(I)的方法。